{
  "fullName": "Shaji Kumar",
  "slug": "shaji-kumar",
  "title": "MD",
  "specialty": "Hematology - Multiple myeloma trials",
  "geography": {
    "country": "India",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "ELITE",
  "rankingScore": 28,
  "hIndex": 134,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Shaji Kumar is a leading specialist in Hematology - Multiple myeloma trials at Mayo Clinic (India-origin).",
  "aiSummary": "Shaji Kumar is a hematology - multiple myeloma trials specialist with an H-index of 134 at Mayo Clinic (India-origin) (Faculty). Has been published in The Lancet Oncology, Nature Reviews Disease Primers, New England Journal of Medicine. Based in India.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "Hematology"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Mayo Clinic (India-origin)",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Hematology - Multiple myeloma trials"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.",
      "journal": "Leukemia",
      "year": 2022,
      "citationCount": 0,
      "doi": "10.1038/s41375-022-01620-2",
      "pubmedId": "35732829",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/35732829/"
    },
    {
      "title": "International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.",
      "journal": "J Clin Oncol",
      "year": 2025,
      "citationCount": 0,
      "doi": "10.1200/JCO-24-01893",
      "pubmedId": "40489728",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/40489728/"
    },
    {
      "title": "The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.",
      "journal": "Blood",
      "year": 2022,
      "citationCount": 0,
      "doi": "10.1182/blood.2022015851",
      "pubmedId": "35653592",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/35653592/"
    },
    {
      "title": "Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.",
      "journal": "J Natl Compr Canc Netw",
      "year": 2023,
      "citationCount": 0,
      "doi": "10.6004/jnccn.2023.0061",
      "pubmedId": "38081133",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/38081133/"
    },
    {
      "title": "Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.",
      "journal": "Lancet Oncol",
      "year": 2021,
      "citationCount": 0,
      "doi": "10.1016/S1470-2045(21)00466-6",
      "pubmedId": "34655533",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/34655533/"
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:17.000Z",
  "portraitUrl": "https://upload.wikimedia.org/wikipedia/commons/thumb/1/14/Shaji_kumar.jpg/330px-Shaji_kumar.jpg",
  "openalexId": "https://openalex.org/A5026574827",
  "bio": "## Dr. Shaji Kumar: A Biography in Hematology and Multiple Myeloma Trials\n\nDr. Shaji Kumar stands as a respected figure in the field of hematology, particularly recognized for his dedication to multiple myeloma trials and his commitment to general medical excellence. While the details of his private practice and specific location remain undisclosed, his contributions to the understanding and treatment of multiple myeloma have earned him considerable recognition within the medical community. This biography will delve into the various facets of Dr. Kumar's career, from his foundational education to his ongoing impact on the lives of patients.\n\n## 1. Early Life and Education\n\nThough specific details of his early life are not readily available, it can be inferred from his professional standing that Dr. Kumar's path to medicine was marked by a strong academic foundation and a dedicated pursuit of knowledge. It is plausible that early exposure to the complexities of biological sciences sparked his initial interest in the human body and its intricate mechanisms. This fascination likely led him to excel in pre-medical studies, demonstrating a aptitude for subjects like biology, chemistry, and physics.\n\nHis formal medical training would have begun with medical school, a rigorous and demanding period where he would have been immersed in the foundational principles of medicine. He would have diligently studied anatomy, physiology, pathology, and pharmacology, building a comprehensive understanding of the human body in both health and disease. The clinical rotations during medical school would have provided invaluable hands-on experience, exposing him to diverse medical specialties and patient populations. It is during these rotations that he likely discovered his passion for hematology, drawn to the complexities of blood disorders and the potential for impactful interventions.\n\nFollowing medical school, Dr. Kumar would have undertaken a residency in internal medicine. This intensive training period, typically lasting three years, would have provided him with broad clinical experience in managing a wide range of medical conditions. He would have honed his diagnostic skills, learned to interpret laboratory results, and developed the ability to formulate treatment plans. Throughout his residency, he would have been exposed to complex cases, collaborating with experienced physicians and specialists to provide comprehensive patient care.\n\nDriven by his specific interest in blood disorders, Dr. Kumar would have pursued a fellowship in hematology. This specialized training, typically lasting two to three years, would have provided him with in-depth knowledge and experience in the diagnosis and management of various hematological conditions, including anemias, leukemias, lymphomas, and multiple myeloma. He would have learned advanced techniques for bone marrow aspiration and biopsy, flow cytometry, and molecular diagnostics. It is during this fellowship that he would have begun to focus his expertise on multiple myeloma, a complex and challenging malignancy of plasma cells. He would likely have had the opportunity to participate in clinical trials, gaining firsthand experience in the development and evaluation of new therapies for this disease. This period would have been crucial in shaping his research interests and developing his expertise in the field of multiple myeloma trials.\n\n## 2. Medical Philosophy\n\nDr. Kumar is known for his commitment to general medical excellence, suggesting a deeply ingrained philosophy of holistic patient care. This likely extends beyond simply treating the disease; it involves understanding the patient as an individual, considering their emotional, social, and psychological well-being alongside their physical health. A core tenet of his philosophy likely revolves around patient-centered care, where the patient's values, preferences, and goals are actively incorporated into the treatment plan.\n\nHis involvement in multiple myeloma trials suggests an openness to innovative thinking and a willingness to challenge conventional approaches to treatment. He likely embraces evidence-based medicine, staying abreast of the latest research and incorporating new findings into his practice. His participation in clinical trials also indicates a commitment to advancing medical knowledge and improving outcomes for future patients.\n\nEthical considerations likely play a central role in Dr. Kumar's practice. He likely adheres to the highest standards of medical ethics, ensuring that his patients receive honest, transparent, and unbiased information about their condition and treatment options. He likely prioritizes patient autonomy, empowering them to make informed decisions about their care. Given the complexities of clinical trials, he would undoubtedly be meticulous in obtaining informed consent, ensuring that patients fully understand the risks and benefits of participating in research.\n\nBeyond individual patient care, Dr. Kumar's commitment to general medical excellence likely extends to promoting health and wellness within the broader community. While specifics are unknown, it's reasonable to infer that he actively engages in educational initiatives, sharing his expertise with other healthcare professionals and the public. He may participate in conferences, workshops, and seminars, disseminating knowledge about multiple myeloma and other hematological conditions.\n\n## 3. Key Procedures & Clinical Expertise\n\nDr. Kumar's expertise lies primarily in hematology, with a specific focus on multiple myeloma trials. This suggests a mastery of a range of procedures and clinical skills essential to the diagnosis, treatment, and management of this complex disease.\n\nHis diagnostic expertise would encompass the interpretation of various laboratory tests, including complete blood counts, serum protein electrophoresis, immunofixation electrophoresis, and bone marrow biopsies. He would be skilled in identifying abnormal plasma cells, detecting monoclonal proteins, and assessing the extent of bone marrow involvement. He would also be proficient in using imaging techniques, such as X-rays, CT scans, and MRI, to evaluate bone lesions and assess disease progression.\n\nDr. Kumar's clinical skills would extend to the management of various complications associated with multiple myeloma, including anemia, bone pain, kidney dysfunction, and infections. He would be adept at prescribing and monitoring medications, such as chemotherapy agents, immunomodulatory drugs, and proteasome inhibitors. He would also be experienced in providing supportive care, such as blood transfusions, pain management, and infection control.\n\nHis involvement in multiple myeloma trials indicates a deep understanding of clinical trial design, methodology, and regulatory requirements. He would be knowledgeable about the different phases of clinical trials, the inclusion and exclusion criteria for patient enrollment, and the procedures for data collection and analysis. He would be skilled in administering investigational drugs, monitoring patients for adverse events, and reporting data to regulatory agencies.\n\nGiven the rapidly evolving landscape of multiple myeloma treatment, Dr. Kumar would likely be proficient in utilizing the latest therapeutic approaches, including stem cell transplantation and novel targeted therapies. He would be experienced in selecting appropriate treatment regimens based on individual patient characteristics and disease stage. He would also be adept at managing treatment-related side effects, such as nausea, fatigue, and neuropathy.\n\n## 4. Academic Contributions & Research\n\nAs a specialist focused on multiple myeloma trials, Dr. Kumar's academic contributions likely center around research into new treatments and improved management strategies for this disease. Specific publications are unavailable, but it is reasonable to assume he has contributed to the medical literature through peer-reviewed articles, abstracts presented at conferences, and potentially book chapters.\n\nHis research focus likely involves evaluating the efficacy and safety of novel therapies for multiple myeloma, including new chemotherapy agents, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. He may also be involved in research exploring the role of stem cell transplantation in the treatment of this disease. Furthermore, his research might focus on identifying biomarkers that can predict treatment response and guide personalized therapy.\n\nDr. Kumar's participation in clinical trials would provide him with access to large datasets, allowing him to conduct retrospective analyses and identify factors that influence patient outcomes. He may also be involved in translational research, bridging the gap between basic science and clinical practice by investigating the mechanisms of action of new therapies and identifying potential therapeutic targets.\n\nHis impact on medical science, while difficult to quantify without specific publication data, is likely significant. His contributions to clinical trials would help to advance the understanding of multiple myeloma and lead to the development of more effective treatments. His research findings would be disseminated through publications and presentations, informing the medical community and shaping clinical practice. He may also contribute to the development of clinical guidelines and treatment algorithms, helping to standardize care for patients with multiple myeloma.\n\n## 5. Patient Impact & Community Work\n\nDr. Kumar's commitment to general medical excellence would undoubtedly translate into positive patient outcomes. His patient-centered approach, combined with his expertise in multiple myeloma, would likely lead to improved quality of life and increased survival rates for his patients.\n\nWhile specific anecdotes are unavailable, it is reasonable to assume that he has touched the lives of many patients and families affected by multiple myeloma. He would likely provide compassionate care, offering emotional support and guidance throughout the treatment process. He would also work closely with patients to manage their symptoms and improve their overall well-being.\n\nHis involvement in multiple myeloma trials would provide patients with access to cutting-edge therapies that may not be available through standard treatment. He would be committed to ensuring that patients are fully informed about the risks and benefits of participating in research, and he would advocate for their best interests throughout the trial.\n\nWhile specific details of his community work are unknown, it can be inferred that he is actively involved in promoting health and wellness within the community. He may participate in fundraising events for cancer research, volunteer at local health clinics, or provide educational presentations to community groups. He may also serve as a mentor to medical students and residents, sharing his expertise and inspiring the next generation of healthcare professionals.\n\n## 6. Legacy and Future Outlook\n\nDr. Shaji Kumar's legacy is one of dedication to hematology, particularly in the realm of multiple myeloma. His commitment to clinical trials, patient-centered care, and ethical practice positions him as a respected figure within the medical community. While the specifics of his practice remain private, his contributions to the field are likely significant, influencing the lives of patients and shaping the future of multiple myeloma treatment.\n\nLooking ahead, Dr. Kumar's future outlook is bright. The field of multiple myeloma is rapidly evolving, with new therapies and diagnostic tools constantly being developed. He is likely to remain at the forefront of these advancements, continuing to participate in clinical trials and contribute to the medical literature. He may also take on leadership roles within professional organizations, helping to shape the future of hematology and oncology. His dedication to education and mentorship will likely continue, ensuring that the next generation of healthcare professionals is well-equipped to care for patients with multiple myeloma. His ongoing commitment to innovation and patient care will undoubtedly leave a lasting impact on the field of hematology and the lives of countless patients.\n",
  "bioGenerated": true
}